Key Metrics of XTL Biopharmaceuticals Ltd.
Revenue—FY 2020
Operating income−$948K▲ 0.0% YoY
Net profit−$3.0M▲ 0.0% YoY
Shareholders' equity$3.6M
Market cap$4.8MXTLB · $1.97
Competitors10identified
About XTL Biopharmaceuticals Ltd.
Sectors
Company details
- Listed
- Nasdaq: XTLB
Operational Areas of XTL Biopharmaceuticals Ltd.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameXTL Biopharmaceuticals Ltd.
TickerXTLB
ExchangeNasdaq
CountryIsrael
SEC CIK0001023549
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
XTLB · Nasdaq · SEC CIK 0001023549
Last price · 23 Oct 2026
$1.97
+5.35%
Market cap$4.8M
P/E—On FY 2020 diluted EPS
Volume10,360
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOIsrael
XTLB share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of XTL Biopharmaceuticals Ltd.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.